Pathogenesis and mechanisms of neurodegeneration, development of therapeutic interventions for neurological disorders
Selected publications
Sex-specific biphasic alpha-synuclein response and alterations of interneurons in a COVID-19 hamster model
eBioMedicine 2024 10.1016/j.ebiom.2024.105191
Blood-brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy
Transl Neurodegener 2024 10.1186/s40035-024-00430-z
Infections in the etiology of Parkinson’s disease and synucleinopathies: a renewed perspective, mechanistic insights and therapeutic implications
Journal of Parkinsons Disease 2024 10.3233/jpd-240195
Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing α-Synuclein
Movement Disorders 2023 10.1002/mds.29398
CYP19A1 mediates severe SARS-CoV-2 disease outcome in males
Cell Reports Med 2023 10.1016/j.xcrm.2023.101152
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies
npj Parkinson's Disease 2023 10.1038/s41531-023-00547-4
A Mouse Model to Test Novel Therapeutics for Parkinson’s Disease: an Update on the Thy1-aSyn (“line 61”) Mice
Neurotherapeutics 2023 10.1007/s13311-022-01338-0
Microgliosis and neuronal proteinopathy in brain persist beyond viral clearance in SARS-CoV-2 hamster model
eBioMedicine 2022 10.1016/j.ebiom.2022.103999
Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease
Neurobiol Dis 2021 10.1016/j.nbd.2021.105478
A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
Acta Neuropathol 2021 10.1007/s00401-021-02349-5
Alpha-Synuclein Pathology Coincides With Increased Number of Early Stage Neural Progenitors in the Adult Hippocampus
Fron Cell Dev Biol 2021 10.3389/fcell.2021.691560
Optogenetic augmentation of the hypercholinergic endophenotype in DYT1 knock-in mice induced erratic hyperactive movements but not dystonia
EBioMedicine 2019 10.1016/j.ebiom.2019.02.04
Lighting Up Alpha-synuclein Oligomers
EBioMedicine 2018 10.1016/j.ebiom.2018.02.016
Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson’s Disease
Molecular Therapy Nucleic Acids 2017 https://doi.org/10.1016/j.omtn.2017.08.013
Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice
Neurobiology of Aging 2017 10.1016/j.neurobiolaging.2016.11.015
A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy
Neurotherapeutics 2014 10.1007/s13311-014-0294-x
Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons
Neurobiology of Disease 2014 10.1016/j.nbd.2014.05.012
Genetic animal models of dystonia: Common features and diversities
Progress in Neurobiology 2014 10.1016/j.pneurobio.2014.07.002
Modelling of Parkinson's disease in mice
Lancet Neurology 2011 10.1016/s1474-4422(11)70227-7
